Britain's biggest drug maker, which has endured a difficult few weeks as the safety of its diabetes drug Avandia came under scrutiny from American regulators, yesterday revealed a pre-tax loss of £97m for the second quarter compared to a £2.1bn profit the previous year.
via telegraph.co.uk
No comments:
Post a Comment